Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES ：抗原呈递后BTLA对CD8+T细胞具有多种作用

2017-10-29 MedSci MedSci原创

CD8+T细胞BTLA细胞免疫治疗
关注

利用自体肿瘤浸润淋巴细胞（TIL）进行过继T细胞治疗在转移性黑色素瘤患者中总临床反应率在40%-50%。输入的CD8+肿瘤浸润淋巴细胞BTLA表达与更好的临床结局有关。CLIN CANCER RES近期发表了一篇文章，研究CD8+BTLA+TIL亚群的功能特点以及BTLA中的Grb2在T细胞共刺激中发挥的作用。

利用自体肿瘤浸润淋巴细胞（TIL）进行过继T细胞治疗在转移性黑色素瘤患者中总临床反应率在40%-50%。输入的CD8+肿瘤浸润淋巴细胞BTLA表达与更好的临床结局有关。CLIN CANCER RES近期发表了一篇文章，研究CD8+BTLA+TIL亚群的功能特点以及BTLA中的Grb2在T细胞共刺激中发挥的作用。

作者在人CD8+TIL和鼠CD8+T细胞中研究BTLA发挥的作用及BTLA下游信号。使用的功能研究方法包括单细胞分析，RPPA，抗原特异性疫苗模型联合过继TCR转基因T细胞以及使用免疫缺陷NSG肿瘤负荷鼠构建PDX模型并使用自体TIL细胞进行干预。研究结果表明，CD8+BTLA-TIL细胞在体内不能控制肿瘤生长，抗原特异性CD8+BTLA-T细胞对疫苗的反应受损。但是，CD8+BTLA+TIL细胞在杀伤肿瘤靶标后生存期延长并且持续杀伤能力得到提升。研究还发现Grb2通过增强IL-2分泌和TCR激活后Src活化调节共刺激功能。

文章最后认为，BTLA作为分子具有对已激活的CD8+T细胞同时提供共刺激和共抑制信号的能力，可以导致细胞生存期延长，改善肿瘤控制情况以及产生功能性记忆应答

原始出处：
Krit Ritthipichai,Cara L.Haymaker,et al.Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.CLIN CANCER RES.October 2017 doi:10.1158/1078-0432.CCR-16-1217

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784046, encodeId=bf201e840461b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Mar 30 04:38:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605372, encodeId=835016053e2c8, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623261, encodeId=42c11623261ae, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256982, encodeId=f47b2569827e, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Oct 29 15:42:37 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256967, encodeId=d89425696e30, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Oct 29 13:41:32 CST 2017, time=2017-10-29, status=1, ipAttribution=)]
    2018-03-30 gds2009

    #D8+T#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1784046, encodeId=bf201e840461b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Mar 30 04:38:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605372, encodeId=835016053e2c8, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623261, encodeId=42c11623261ae, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256982, encodeId=f47b2569827e, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Oct 29 15:42:37 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256967, encodeId=d89425696e30, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Oct 29 13:41:32 CST 2017, time=2017-10-29, status=1, ipAttribution=)]
    2017-10-31 ms691033630344116

    #CD8#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1784046, encodeId=bf201e840461b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Mar 30 04:38:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605372, encodeId=835016053e2c8, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623261, encodeId=42c11623261ae, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256982, encodeId=f47b2569827e, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Oct 29 15:42:37 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256967, encodeId=d89425696e30, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Oct 29 13:41:32 CST 2017, time=2017-10-29, status=1, ipAttribution=)]
    2017-10-31 xiaoyeshuang

    #抗原#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1784046, encodeId=bf201e840461b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Mar 30 04:38:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605372, encodeId=835016053e2c8, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623261, encodeId=42c11623261ae, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256982, encodeId=f47b2569827e, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Oct 29 15:42:37 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256967, encodeId=d89425696e30, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Oct 29 13:41:32 CST 2017, time=2017-10-29, status=1, ipAttribution=)]
    2017-10-29 天涯183

    非常好的文章.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1784046, encodeId=bf201e840461b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Mar 30 04:38:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605372, encodeId=835016053e2c8, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623261, encodeId=42c11623261ae, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Tue Oct 31 02:38:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256982, encodeId=f47b2569827e, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sun Oct 29 15:42:37 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256967, encodeId=d89425696e30, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Oct 29 13:41:32 CST 2017, time=2017-10-29, status=1, ipAttribution=)]
    2017-10-29 131****1460

    学习了受益匪浅

    0

相关资讯

燃烧吧！脂肪~（看CD8+T细胞如何消灭肿瘤）

众所周知，通过游泳、竞走等运动方式可减少脂肪、增加肌肉、使身体变得轻盈敏捷从而保持健康。从分子生物学角度，“燃烧脂肪”（促进脂肪酸的破裂）还具有延长癌症患者T细胞存活时间，调节肿瘤微环境的免疫学功能。Nature Review Cancer 的一篇综述佐证了这一观点。

上海研发新型疫苗 有望终身抗流感

记者昨日从上海市（复旦大学附属）公共卫生临床中心获悉，由该中心徐建青研究员领衔的课题组与墨尔本大学合作，历经一年半艰辛研究，首次发现有一种对人体有临床保护作用、有流感“杀手”之称的特异性免疫细胞（CD8阳性T细胞），这一细胞的发现使研制出可保护机体抵抗各种新出现的流感的疫苗成为可能。时下，人们为什么对打疫苗预防流感不感兴趣，就是因为随着病毒的变异，原先打的疫苗就根本起不到预防作用，而且流感病毒几乎

重大突破：复旦大学徐建青有望终结流感

如果只需要注射一次疫苗就可以终身不得流感，这该多好啊。现在科学家们似乎找到了制造这种疫苗的关键。复旦大学和墨尔本大学的研究人员发现，有一种杀死流感的免疫细胞可以记住病毒株。这项研究发表在五月十三日的Nature Communications杂志上，文章的通讯作者是复旦大学的徐建青（Jianqing Xu）研究员和墨尔本大学的Katherine Kedzierska。据介绍，这一发现可以帮助人们开发

Baidu
map
Baidu
map
Baidu
map